The aim — is to study the expression of the anti-apoptotic survivin protein, as well as the expression of the BIRC5 gene of its encoding primary breast carcinoma as a potential procnostic and predictive marker. Material and methods. With the help of immunohistochemistry (IHC), as well as polymerase chain reaction in real time (real-time PCR), 67 samples (biopsy) of the primary breast carcinoma were studied for the presence of expression of the survivin protein and the gene of its encoding BIRC5. Results. Expression of survivin was determined in 47 mammary carcinoma samples, which was 70.15%. Expression of survivin was most often determined in medium and high grade ductal carcinoma (G2—G3), and was associated with lymphovenous stromal invasion (LVSI+). Expression of the survivin protein correlated with the expression of HER2-neu. In 59.6% of cases, survivin was expressed in tumors with a low Ki-67 index. Most often, survivin was expressed with luminal A and luminal B molecular-biological tumor subtype. Real-time PCR determined the expression of the BIRC5 gene in all 67 carcinoma samples. The level of normalized expression of the BIRC5 gene significantly moderately correlated with the expression of the own product of the survivin protein (r=0.704; p<0.01) and slightly correlated with the expression of the oncoprotein HER2-neu (r= –0.285; p<0.05). Conclusion. Expression of the protein of survivin and its gene BIRC5, can be considered as an unfavorable prognostic factor and used as a predictive and prognostic marker.